Abstract
In 2012, the Banff Working Group on Liver Allograft Pathology published a review article on how biopsy findings should be used to adjust immunosuppressive therapy, including weaning of immunosuppression, evaluation of operational tolerance and antibody-mediated rejection (AMR). The liver sessions of the Banff Conference held in 2013 focused primarily on diagnostic criteria of AMR. The next consensus document is in preparation for liver allograft AMR, including histologic findings, interpretation of C4d staining, and correlation with serologic testing. The relationship between chronic AMR and possible effects on liver allograft fibrosis is uncertain and in need of further study.
